Current Liabilities
Operating Lease Liability Payments Due
Neurocrine Biosciences Operating Lease Liability Payments Due decreased by 4.7% to $590.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.6%, from $645.90M to $590.20M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ2 2020
Last reportedQ1 2026May 5, 2026
How to read this metric
Rising liabilities indicate growing operational footprint or lease renewals, while falling liabilities may signal cost-cutting or consolidation of facilities.
Detailed definition
This represents the total future cash payments required for operating leases, typically categorized by maturity periods...
Peer comparison
Standardized under ASC 842, this metric is highly comparable across all public companies with significant physical operations.
Metric ID:
operating_lease_liability_payments_dueHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $159.30M | $155.70M | $150.30M | $146.00M | $141.70M | $132.90M | $130.70M | $126.10M | $377.40M | $381.00M | $372.10M | $645.90M | $636.50M | $619.50M | $590.20M |
| QoQ Change | — | -2.3% | -3.5% | -2.9% | -2.9% | -6.2% | -1.7% | -3.5% | +199.3% | +1.0% | -2.3% | +73.6% | -1.5% | -2.7% | -4.7% |
| YoY Change | — | — | — | -8.3% | -9.0% | -11.6% | -10.5% | -11.0% | +184.0% | +191.5% | +195.1% | +71.1% | +67.1% | +66.5% | -8.6% |
Range$126.10M – $645.90M
CAGR+45.4%
Avg YoY Growth+59.7%
Median YoY Growth+29.1%
Current Streak3 quarters decline
Operating Lease Liability Payments Due at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating lease liability payments due?
- Neurocrine Biosciences (NBIX) reported operating lease liability payments due of $590.20M in Q1 2026.
- How has Neurocrine Biosciences's operating lease liability payments due changed year-over-year?
- Neurocrine Biosciences's operating lease liability payments due decreased by 8.6% year-over-year, from $645.90M to $590.20M.
- What does operating lease liability payments due mean?
- The total future cash payments the company is contractually obligated to make for operating leases.